Confo Therapeutics
Edward currently serves on the supervisory boards of Azafaros, Escalier BioSciences, Genase Therapeutics, Scenic Biotech, Staten Biotechnology, Synaffix and TigaTx. He served on the supervisory boards of Progentix Orthobiology (acquired by Nuvasive ), Noviogendix (acquired by MDxHealth) and was founding investor and supervisory board member of Acerta Pharma (acquired by Astra Zeneca). Edward is also on the board of Mibiton.
Edward started his career as process engineer for Chiron Inc.. He subsequently worked in product development and corporate licensing at Johnson & Johnson. Since 2000 he expanded his experience as CEO of several life sciences companies in the Netherlands.
Edward holds a M.Sc. in chemistry from the University of Utrecht and a M.Sc in Biochemical Engineering from the Delft University of Technology.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Confo Therapeutics
1 followers
Confo Therapeutics is an emerging drug discovery company built around a disruptive technology to enable the discovery of GPCR agonists. The CONFO® technology uses single domain antibodies to lock inherently unstable GPCRs in the druggable conformation and uses this stabilized complex as a superior starting point for GPCR drug discovery.